Investor Centre

Investor Fact Sheet

Open 0.06
High 0.07
Low 0.06
Volume 00
Up 0.01
(Up 8.3%
As at 3:57PM 11/07/2024

Investor Fact Sheet

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

Key Corporate Details

Key Corporate Details Incorporated 1998

Acrux is listed on the Australian Stock Exchange (ASX)

ABN: 72 082 001 152

Registered Office and Principal Business Address:
103-113 Stanley Street, West Melbourne, Victoria, 3003, Australia
Telephone: +61 3837 90100


Board of Directors

Ross Dobinson - Chair and Non-Executive Director
Michael Kotsanis - Managing Director and Chief Executive Officer
Geoff Brooke - Non-Executive Director
Don Brumley - Non-Executive Director, Chair Audit and Risk Committee
Tim Oldham - Non-Executive Director, Chair Human Capital and Nominations Committee

Executive Team

Felicia Colagrande - Product Development and Technical Affairs Director
Mark Hyman - Project and Technical Director
Joanna Johnson - Company Secretary and Chief Financial Officer


103-113 Stanley Street West Melbourne VIC 3003 Australia

Share Registry

Link Market Services
Level 13, Tower 4, 727 Collins Street,
Docklands, Victoria, 3008, Australia

Telephone: +61 1300 554 474 (toll free within Australia)


Pitcher Partners
Level 13, 664 Collins Street,
Docklands VIC 3008

Key Events and Dates

 February  Reporting of Half Year Financial Statements
 30 June  Financial Year End
 August  Reporting of Full Year Financial Statements
 September  Closing date for receipt of director nominations before AGM
 November  AGM 
 31 December  Financial Half Year End

Details regarding date and location of AGM, as well as business to be dealt with, to be included in Notice of Meeting, announced to ASX and sent to shareholders at least 28 days prior to the meeting.